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OBJECTIVES: Little is known about the use and effectiveness of new treatments for
metastatic renal cell carcinoma (mRCC) in daily practice. In the Netherlands, this
information is needed for expensive inpatient drugs to guarantee continued reim-
bursement. We evaluated the use and effectiveness of bevacizumab plus interferon
alfa-2a (IFN) for patients with mRCC in Dutch daily practice. METHODS: A popula-
tion-based registry was created to include patients newly diagnosed with mRCC
from 2008-2010. These patients represent 55% of all patients in the Netherlands.
Data were collected on patient and disease characteristics, treatments, dosages,
treatment response, survival, adverse events and resource use. RESULTS: To date,
data on 615 patients have been collected. Average age at diagnosis was 66.4 years
(range: 23-93) and 66% was male. 53% of these patients received systemic therapy.
The majority (83%) was treated with sunitinib, whereas sorafenib is most often
used as second-line treatment. Data from 34 patients treated with bevacizumab
plus IFN in the first line were collected. The dosage corresponded with the recom-
mended dosage (10 mg/kg). Since the mean weight of patients in daily practice was
higher than the mean weight seen in the phase III trial (87.5 vs 76.0 kg), the mean
dosage was also higher. Of the 34 patients treated with bevacizumab plus IFN,
median overall survival was similar to that seen in the phase III trial (23.0 vs 23.3
months).CONCLUSIONS: Feasibility issues come into play when evaluating the use
and effectiveness of expensive inpatient drugs in daily practice. Since bevaci-
zumab plus IFN is not regularly used in daily practice, future cost-effectiveness
analyses will have to be based on a careful synthesis of evidence from daily prac-
tice, the phase III trial, quality of life studies and other sources.
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A SYSTEMATIC REVIEW OF THE HETEROGENEITY OF TREATMENT EFFECT IN
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OBJECTIVES: Clinical studies typically assess average treatment effect on out-
comes, potentially ignoring heterogeneity of treatment effect associated with phe-
notypic and genotypic characteristics. A paradigm shift where drugs are targeted to
disease subtypes based on molecular biomarkers, rather than phenotypic or histo-
logical characteristics alone, is underway and beginning to influence outcomes
research. Our objective was to assess heterogeneity of treatment effect associated
with adjuvant and advanced-stage therapy for OC and strength of evidence docu-
menting association between patient or tumor characteristics and outcomes.
METHODS: We conducted a review according to the Cochrane Handbook of Sys-
tematic Reviews, with two independent reviewers completing study selection from
11 databases and data extraction on several outcomes: overall survival (OS), pro-
gression-free survival (PFS), tumor response, disease-free survival, time to progres-
sion, adverse events, and quality of life (QOL). Studies that did not evaluate char-
acteristics identified as predictive of anti-cancer treatment outcome, regardless of
whether treatment was molecularly targeted, were excluded. Descriptive analyses
were conducted. RESULTS: Forty-seven of 554 publications were selected (93%
concordance between reviewers). Most studies presented post-hoc analyses (45/
47); over half evaluated platinum-taxane combinations (27/47). Fifty-three distinct
patient or tumor characteristics were evaluated for association with outcomes.
Nine of the 10 most frequently studied characteristics were molecular: p53, VEGF,
ERCC1, CA-125, CD31-MVD, stathmin, TSP1-1A, III-tubulin and CD24. No studies
assessed predictive factors for QOL. Elevated CA-125 and stathmin levels were each
predictive of worsening OS and PFS, and VEGF levels or genotype were mostly
unrelated to OS or PFS. CONCLUSIONS: There are numerous studies that associate
mostly molecular markers with traditional measures of treatment effect; however,
patient-centered outcomes in this context have not yet been studied in OC. Future
evaluations of treatment effect in OC should also consider variation in these pa-
tient and tumor characteristics, in addition to histological and phenotypic charac-
teristics, for association with QOL.
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OBJECTIVES:To compare overall survival (OS) and progression free survival (PFS) in
sunitinib-refractory (SU-r) patients with mRCC treated with AXI and BSC using STC.
METHODS: STC method was used to derive OS and PFS curves for a hypothetical
cohort of “AXI-like” patients had they received BSC in the AXIS trial. Patient level
data on SU-r patients from the AXIS trial were used to derive predictive equations
for OS and PFS. Parametric survival analysis identified the best fitting distribution
and significant predictors of OS and PFS. These equations were calibrated using
patient characteristics and mPFS and cross-over adjusted mOS of the BSC cohort in
the RECORD-1 trial. RESULTS: In AXIS all 194 SU-r AXI patients progressed on one
line of treatment. In RECORD-1 78% of BSC patients had 2 prior lines and some
failed 1st line treatment due to intolerability. Other available patient characteristics
were comparable except for MSKCC risk category (36% vs 15% poor risk, AXI vs BSC
respectively) and ECOG score (52% vs 68% with ECOG 0). The final predictive equa-
tions using the best-fitting log-normal distribution included MSKCC risk group and
age for PFS, and MSKCC risk category and duration of prior SU for OS. Median
estimated OS and PFS was 15.2 and 5.1 months for AXI compared to 8.3 and 1.6
months for BSC respectively. Estimated difference in mean OS and PFS between
AXI and BSC was 11.4 and 5.9 months. Sensitivity analyses using patient charac-
teristics of the SU-r subgroup of everolimus arm and Weibull distribution showed
similar results. CONCLUSIONS: The STC analysis, an alternative to mixed treat-
ment comparison, suggested a significant improvement in OS and PFS for SU-r
mRCC patients treated with AXI compared to BSC. However, the analysis could not
account for all the differences between patient populations, particularly for the
number of prior non-VEGFR-TKI therapies.
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OBJECTIVES: With increasing health care resource constraints, it is important to
understand the incremental cost-effectiveness (ICER) of new medicines, and an
integral effort is to predict key clinical and economic outcomes over the patients’
lifetime. Our objective was to predict the lifetime mean overall survival (OS) and
bone metastasis-free survival (BMFS) for denosumab (120mg subcutaneous every 4
weeks) vs. placebo in men with CRPC based on a recent phase III trial (ClinicalTri-
als.gov NCT00286091).METHODS: A three-state health state model (BMFS, BM pro-
gression, and Death) was developed. Parametric survival functions for OS and
BMFS were estimated using trial data and extrapolated for lifetime. Model selection
was based on the best fit within trial duration (AIC criteria), and overall shape of the
lifetime predictions. For the parametric estimation, consistent with trial results,
pooled data from both study arms were used for OS; the placebo arm was used for
the baseline BMFS and the trial reported treatment effect (HR) was applied to derive
the BMFS curve for denosumab. RESULTS: A Weibull function was identified as the
best fit for both OS and BMFS. The pooled mean estimate was 4.02 years for OS, and
2.75 and 3.16 years for BMFS in placebo and denosumab respectively, resulting in
an incremental BMFS of 0.41 year for denosumab vs placebo. CONCLUSIONS: De-
nosumab treatment is predicted to prolong time in BMFS, which will reduce time in
BM progression state with potentially lower costs and costs offsets for denosumab
from reduced need of routine care in the metastatic health state. This finding will
facilitate our understanding of the ICER of denosumab in men with CRPC at high
risk of developing BM.
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OBJECTIVES: Chemotherapy-induced nausea and vomiting (CINV) is a significant
adverse effect of cancer chemotherapy treatment. The 5-hydroxytryptamine-3 re-
ceptor antagonists (5-HT3-RAs), a class of antiemetics, is indicated for the preven-
tion and treatment of CINV. The purpose of this study was to examine the use of
rescue antiemetic administration for CINV in patients diagnosed with cancer and
undergoing single-day chemotherapy. METHODS: A retrospective cohort analysis
using the Ingenix LabRx® database was conducted. Adult patients diagnosed with
lung, breast, or colon cancer, treated with a moderately (MEC) or highly emetogenic
chemotherapy (HEC), and who received a prophylactic 5-HT3-RA from 4/1/08 to
3/31/09, were identified. The outcome of interest was the rate of rescue antiemetic
administration, per cycle of chemotherapy, between 5-HT3-RA treatment cohorts.
Rescue antiemetic utilization was defined by a HCPCS code for administration of an
antiemetic from day 2 to the end of the cycle or for 30 days following single-day
chemotherapy. RESULTS A total of 5,912 patients were identified, 25.7% treated
with a HEC regimen and 74.3% on a MEC regimen.The mean age was 56.1 years and
77.1% were female. Patients were treated with a total of 21,821 cycles of chemo-
therapy. The most common 5-HT3-RA utilized was palonosetron (73% of cycles)
followed by ondansetron (11%), granisetron (10%), and dolasetron (6%). The overall
unadjusted rate of rescue antiemetic administration per cycle was 17.6%, and the
rate differed by 5-HT3-RA utilized. Patients treated with palonosetron were signif-
icantly less likely to require a rescue antiemetic on a per cycle basis (14.1%), com-
pared to patients treated with another 5-HT3-RA (26.6%), p.001. CONCLUSIONS:
The results from this retrospective analysis suggest that rescue antiemetic utiliza-
tion may be significantly reduced in patients undergoing chemotherapy following
use of palonosetron vs. another 5-HT3-RA for the prevention of CINV.
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OBJECTIVES: While persistence with drug therapy is essential to achieve optimal
patient benefits, poorly controlled MM results in earlier disease progression, dis-
ease-related complications, deleteriously impacts quality of life, and ultimately
death. This study assesses the relationship between treatment LEN adherence/
persistence and indicators of lack of disease control and disease-related complica-
tions of MM. METHODS: Commercial and Medicare Advantage enrollees initiating
LEN for treatment of MM with pharmacy and medical benefits in the 6 months prior
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and 1 year following initiation of LEN were identified in a US health plan claims
database (7/1/2007-6/30/2011). Persistence was defined as days from the first LEN
treatment to the earlier of either the date of discontinuation or end of the follow-up
period. Adherence was measured by the medication possession ratio. Indicators of
disease control included in this study were inpatient hospitalization(s) and number
of ER visits. Disease-related complications included evidence of skeletal-related
events (SREs) defined as fracture, spinal cord compression, or radiation to the bone;
and sepsis. RESULTS: Among the 605 patients meeting the inclusion criteria, per-
sistency with lenalidomide averaged 6.0 months (median  4.9) with 57.9% of
patients being persistent for the entire year. A one month increase in persistence
was associated with a lower probability of SREs (OR0.96; p0.078), sepsis
(OR0.86; p0.001), and relapse or disease progression (OR0.78; p0.001). The
probability of an inpatient hospitalization (OR0.68; p-value0.001) and additional
ER visits (OR0.83; p0.002) were both lower with better persistence. A higher
medication possession ratio measured in year 1 was associated with increased
overall survival (p0.007).CONCLUSIONS: This analysis demonstrates that contin-
uous treatment with LEN improves disease control in MM patients, as well as
reduces health care utilization and related costs as indicated by the lower risk of
hospitalizations and fewer ER visits.
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OBJECTIVES: Since 2008, teenage girls are being vaccinated against Human Papil-
lomavirus (HPV) in Europe. The vaccine coverage did not reach high uptake. The
aim of this study is to design a dynamic transmission framework to model HPV-
transmission in the population in order to predict epidemiologic and economic
consequences of population-based HPV vaccination programs. METHODS: A dy-
namic transmission model was designed including 7 different HPV-types to predict
the epidemiologic and economic consequences of HPV-vaccination. Dutch age-
specific HPV-prevalence and cervical cancer incidence and mortality data were
used to calibrate the model assuming a steady state. The consequence of HPV-
vaccination was analyzed in different scenarios. In particular, the age of the vac-
cinee, inclusion of boys, and a reduced screening compliance was assessed. In
sensitivity analyses, the vaccination coverage, duration of vaccine-induced protec-
tion, and vaccine choice was varied. RESULTS: Vaccination of 50% of girls against
HPV infection results in a 56% overall reduction in cervical cancer incidence. The
model predicted outcomes are highly sensitive for the duration of vaccine-induced
protection and the vaccination coverage. If vaccination will only provide 20-years
of protection a 32% reduction in cervical cancer incidence was observed. HPV16 and
18 will be eradicated from the general population if vaccine coverage is 90%.
Vaccination at an older age still provides a relevant number of cases averted how-
ever vaccination before sexual debut remains most efficient. Vaccination of boys
was found to be not an effective alternative. CONCLUSIONS: HPV vaccination was
found to be highly effective in reducing the burden of cervical cancer. The model
predicted outcomes are most sensitive for vaccine-induced duration of protection.
Vaccination of girls at an older age can be considered to further reduce the inci-
dence of cervical cancer.
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OBJECTIVES: The worldwide incidence of melanoma is increasing rapidly. Two
chemotherapy regimens are used for treatment of Malignant Melanoma: single
agent intravenous Dacarbazine (DTIC) and oral Temozolomide (TMZ). TMZ has
greater cost in Iran so we aimed to conduct a meta analysis to compare the efficacy
of two drugs. METHODS: To compare the efficacy of these two drugs, a systematic
review and meta-analysis were conducted and published articles, comparing use
of Dacarbazine and Temozolomide in treatment of Malignant Melanoma were re-
viewed. For this purpose, Pubmed, Scopous, Web of Science and Cochrane Central
Register of Controlled Trials were searched and the search terms were: “Dacarba-
zine” and “Temozolomide” and “ Malignant Melanoma”. Data were collected from
inception to 2012. “Response to treatment” includes:” complete response (CR)”,”
partial response (PR)” and “stable disease (SD)” and side effects were the key out-
comes of interest. RESULTS: The meta-analysis included 3 RCTS and involved 1314
patients with malignant melanoma. Approximately half of them were allocated to
the TMZ arm and half to the DTIC arm. Comparison of TMZ with DTIC yielded a
nonsignificant relative risk (RR) of 0.83 (95% confidence interval of 0.26-2.64,
P0.76) for complete response. A nonsignificant RR of 1.35 (95% CI of 0.95-1.91,
P0.1) for partial response. A nonsignificant RR of 1.05 (95% CI of 0.85-1.3, P0.65)
for stable disease and a nonsignificant RR of 1.15 (95% CI of 0.74-1.79, P0.55) for
fatigue ( a side effect). CONCLUSIONS: The potential value of oral versus intrave-
nous chemotherapy is obvious but considering health outcome and not significant
difference in efficacy between these two drugs and that TMZ even does not have
less side effects and has higher cost of treatment in Iran, we suggest DTIC as a
first-choice treatment for Malignant Melanoma.
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OBJECTIVES: To systematically review the currently available clinical and cost-
effectiveness evidence on proton beam radiotherapy (PBRT) for cancers mostly
affecting the eye: uveal melanoma, retinoblastoma and metastatic tumors.
METHODS: A systematic literature search was conducted for published and un-
published cost-effectiveness and clinical data (comparative studies) on the eye
cancer population, treated with proton radiation, using a number of medical data-
bases (PubMed, EMBASE, Cochrane Library). In addition, clinical trial registries
were searched, reference lists of included studies and of reviews were screened for
missed studies. Searches took place in January 2012. RESULTS: The search gener-
ated 374 references, of which 5 comparative studies met the inclusion criteria. All
were reporting cases of uveal melanoma. Studies were characterized by large dif-
ferences in radiation techniques applied within the studies, and by variation in
patient characteristics within and between studies. Overall, the level of evidence is
low. When compared to iodine-125 or ruthenium-106 brachytherapy, protons did
not provide beneficial effects on overall survival. Proton therapy was although
superior to enucleation: results of two studies showed that 12% more patients
survived over 36 months and 21% more patients survived over 60 months in the
proton group. Vision preservation was observed significantly more frequently after
proton therapy than iodine-125 brachytherapy (97% vs 93.1%, p0.009). Only one
included study reported side effects. Refractory neovascular glaucoma and corneal
perforations were observed after proton therapy and 10.9% eyes treated with PBRT
were enucleated due to complications. No economic evaluation studies were
found. CONCLUSIONS: There is limited evidence on the effectiveness and safety of
proton radiation in patients with ocular melanomas due to the lack of well-de-
signed and well-reported studies. Available comparative studies suggest that pro-
ton beam therapy may be beneficial for patients with uveal melanoma, with, how-
ever, possible serious side effects. There is a need for research establishing its
cost-effectiveness.
PCN16
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OBJECTIVES: To compare clinical efficacy and safety of sunitinib (SUN) and best
supportive care (BSC) versus placebo (PL) and best supportive care (BSC) in the
treatment of patients with unresectable or metastatic, well-differentiated pancre-
atic neuroendocrine tumours (pNET) with disease progression. METHODS: The
review was conducted in accordance with the Cochrane Collaboration guidelines
and the Polish Agency for Health Technology Assessment (AOTM) recommenda-
tions. Calculations were performed using the StatsDirect® 2.6.8 statistical package.
RESULTS: As a result of systematic search of publications, 1 primary randomized
clinical trial (subtype II A), satisfying the inclusion criteria was found (Raymond
2011). It was shown that the use of SUNBSC results in a statistically significant
higher clinical efficacy in respect of progression free survival (PFS), overall survival
(OS) and objective response rate in comparison with the control (PLBSC). The
median PFS was over two fold greater in sunitinib treated patients (11.4 months)
than in placebo group (5.5 months). The objective response rate was 9.3% in the
sunitinib group versus 0% in the placebo group. In the sunitinib group 9 deaths
(10%) were reported compared with 21 deaths (25%) in the placebo group (HR 0.40;
95% CI, 0.18 to 0.86). Sunitinib is safe and well-tollerated therapy. The most fre-
quent adverse events in the sunitinib group were diarrhea, nausea, vomiting, as-
thenia, and fatigue. In most cases, analysed adverse events were of low severity
grade. CONCLUSIONS: The results of the presented analysis clearly prove that
sunitinib administered in a 37,5 mg dose is an effective and safe therapy in the
treatment of patients with unresectable or metastatic, well-differentiated pancre-
atic neuroendocrine tumours with disease progression.
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NON SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR
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OBJECTIVES: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine ki-
nase inhibitor (TKI) that has proven, in controlled clinical trials, to be effective in
the first-line treatment of patients with advanced or metastatic non-small-cell
lung cancer (mNSCLC) with EGFR activating (EGFR) mutations, showing signifi-
cant improvement of progression-free survival over platinum-based standard che-
motherapy. In those trials, pemetrexed was not included in the platinum-based
chemotherapy regimens used as a comparator, since it was not yet approved for
first line use. Following approval as first line treatment for lung adenocarcinoma,
plus cisplatin, it became the standard for this indication. The aim of this analysis
was to compare the efficacy in reducing the risk of disease progression for patients
with mNSCLC with EGFR mutations treated with erlotinib versus pemetrexed/
cisplatin. METHODS: In the absence of head-to-head trials comparing erlotinib
with pemetrexed/ cisplatin, an indirect comparison methodology was performed
using the Hazard Ratio (HR) - the most appropriate measure to compare time re-
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